Cytosine arabinoside in addition to VCAA‐based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
- 6 May 2008
- journal article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 6 (2) , 80-89
Abstract
Cytosine arabinoside (ara‐C) is a component of many protocols for the treatment of acute leukaemia and non‐Hodgkin lymphomas in humans. The aim of the study was to prospectively evaluate the efficacy of ara‐C in a myeloablative regimen in a cohort of canine lymphomas with bone marrow involvement. Seventeen dogs were enrolled. Eight were treated with a VCAA‐based protocol (Group 1) and nine with the same regimen added with ara‐C (Group 2). Ara‐C was administered on a 5‐day schedule as an i.v. continuous infusion at the dose of 150 mg m−2per day for five consecutive days. During treatment complete remission (CR) was achieved in two dogs in Group 1 and in eight dogs in Group 2. CR rate was significantly higher in Group 2 (P < 0.01). Median survival was 72.5 days (range 6–174) in Group 1 and 243 days (range 73–635) in Group 2. Survival was significantly longer in Group 2 (P < 0.001). Both protocols were well tolerated, with a low incidence of adverse events. Ara‐C added to a VCAA‐based protocol appears to be safe and beneficial in dogs with stage V lymphoma. Incorporation of the nucleoside analogue might be crucial for the development of future therapeutic strategies in dogs.Keywords
This publication has 27 references indexed in Scilit:
- Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogsJournal of Small Animal Practice, 2006
- Dexamethasone, Melphalan, Actinomycin D, Cytosine Arabinoside (DMAC) Protocol for Dogs with Relapsed LymphomaJournal of Veterinary Internal Medicine, 2006
- Flow cytometric expression of common antigens CD18/CD45 in blood from dogs with lymphoid malignancies: A semi-quantitative studyVeterinary Immunology and Immunopathology, 2006
- Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD moleculesVeterinary Immunology and Immunopathology, 2005
- Veterinary Co‐operative Oncology GroupVeterinary and Comparative Oncology, 2004
- High-dose cytosine arabinoside in the treatment of acute myeloid leukaemiaBlood Reviews, 1997
- Cytosine arabinoside (Ara‐C) plus alpha‐interferon (αIFN) determine prolonged complete remissions in patients with aggressive non‐Hodgkin's lymphoma partially responsive to first‐line doxorubicin‐containing regimensBritish Journal of Haematology, 1994
- Cytosine Arabinoside as a Single Agent for the Induction of Remission in Canine LymphomaJournal of Veterinary Internal Medicine, 1994
- Canine multicentric lymphoma 2: Comparison of response to two chemothera‐peutic protocolsJournal of Small Animal Practice, 1994
- Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaCancer, 1993